View More Recent Stories
-
Clearmind Medicine (CMND) Announces the Notice of an International Patent Application for Pioneering Ibogaine Combination Therapy
-
Clearmind Medicine (CMND) and Yissum File International Patent Application for Revolutionary Psychedelic Compounds for PTSD Treatment
-
Clearmind Medicine (CMND) Announces Publication of International Patent Application for Innovative MDMA-Based Combination Treatment
-
Clearmind Medicine (CMND) Announces Publication of its Patent Application for Innovative Ketamine-Based Combination Treatment
-
Clearmind Medicine (CMND) Granted U.S. Patent Approval for Binge Behavior Treatment
-
Clearmind Medicine (CMND) and Yissum Expand Collaboration with International Patent Application for Generation 3.0 Psychedelic Compounds to Treat Mental Disorders
-
SciSparc (SPRC) and Clearmind Medicine (CNMD) Announce New Scientific Article Showing MEAI Potential as a Novel Weight Loss Drug
-
Clearmind Medicine (CMND) Signs Agreement to Source Manufacturers and Distributors for its Alcohol Substitute Beverage Product
-
Clearmind Medicine (CMND) Obtains IND Approval from the FDA to Start the Phase I/IIa Clinical Trial with its Treatment for Alcoholism
-
SciSparc (SPRC) Announces U.S. Patent Application for Treating Metabolic Syndrome and Weight Loss
-
Clearmind Medicine (CMND) Granted Patent Approval in HK for its Binge Behaviors Treatment
-
Clearmind Medicine (CMND) Secures Exclusive Global Rights to Innovative Psychedelic Compounds for PTSD Treatment
-
Clearmind Medicine (CMND) announces advancement in its proprietary MEAI- based alcohol substitute beverage program
